Evaluation of the potency of the Anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Mader, Alexander ^a   Kunert, Renate ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTIIDIOTYPIC ANTIBODY 3H6; ANTIIDIOTYPIC ANTIBODY 3H6 FAB FRAGMENT INTERLEUKIN 15 FUSION PROTEIN; ANTIIDIOTYPIC ANTIBODY 3H6 FAB FRAGMENT TETANUS TOXOID FUSION PROTEIN; EPITOPE; GLYCOPROTEIN GP 41; HIV 1 ENVELOPE PROTEIN UG 37; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY 2F5; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DESIGN; DRUG POTENCY; DRUG PURIFICATION; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RABBIT; VACCINATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HUMANS; RABBITS;

EID: 84862503616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039063     Document Type: Article

References (61)

1. HIV/AIDS UJPo, (2010) Global Report: UNAIDS Report on the Global AIDS Epidemic.
2. Plotkin S, (2008) Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47: 401-409.
3. Amanna IJ, Slifka MK, (2009) Wanted, dead or alive: new viral vaccines. Antiviral Res 84: 119-130.
4. Zinkernagel RM, (2003) On natural and artificial vaccinations. Annu Rev Immunol 21: 515-546.
5. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, et al. (2009) Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 284: 30627-30642.
6. Ye L, Wen Z, Dong K, Wang X, Bu Z, et al. (2011) Induction of HIV Neutralizing Antibodies against the MPER of the HIV Envelope Protein by HA/gp41 Chimeric Protein-Based DNA and VLP Vaccines. PLoS One 6: e14813.
7. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, et al. (1994) Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10: 359-369.
8. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, et al. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10: 1651-1658.
9. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, et al. (2004) Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 78: 14039-14042.
10. Kunert R, Steinfellner W, Purtscher M, Assadian A, Katinger H, (2000) Stable recombinant expression of the anti HIV-1 monoclonal antibody 2F5 after IgG3/IgG1 subclass switch in CHO cells. Biotechnol Bioeng 67: 97-103.
11. Kunert R, Rüker F, Katinger H, (1998) Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res Hum Retroviruses 14: 1115-1128.
12. Stoiber H, Frank I, Spruth M, Schwendinger M, Mullauer B, et al. (1997) Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol 34: 855-863.
13. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1757-1765.
14. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
15. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9: 343-346.
16. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433.
17. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84: 1302-1313.
18. Opalka D, Pessi A, Bianchi E, Ciliberto G, Schleif W, et al. (2004) Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods 287: 49-65.
19. Hu SL, Stamatatos L, (2007) Prospects of HIV Env modification as an approach to HIV vaccine design. Curr HIV Res 5: 507-513.
20. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
21. Montero M, van Houten NE, Wang X, Scott JK, (2008) The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 72: 54-84, table of contents.
22. Jerne N, (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373-389.
23. Ladjemi MZ, Chardes T, Corgnac S, Garambois V, Morisseau S, et al. (2011) Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice. Breast Cancer Res 13: R17.
24. Ramos AS, Parise CB, Travassos LR, Han SW, de Campos-Lima PO, et al. (2011) The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma. Cancer Sci 102: 64-70.
25. Lee G, Ge B, (2010) Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunol Immunother 59: 1347-1356.
26. Wang JJ, Li YH, Liu YH, Song J, Guo FJ, et al. (2010) The ability of human bispecific anti-idiotype antibody to elicit humoral and cellular immune responses in mice. Int Immunopharmacol 10: 707-712.
27. de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M, (2007) Anti-idiotype antibodies in cancer treatment. Oncogene 26: 3594-3602.
28. Kunert R, Weik R, Ferko B, Stiegler G, Katinger H, (2002) Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5. AIDS 16: 667-668.
29. Gach J, Quendler H, Weik R, Katinger H, Kunert R, (2007) Partial humanization and characterization of an anti-idiotypic antibody against monoclonal antibody 2F5, a potential HIV vaccine? AIDS Res Hum Retroviruses 23: 1405-1415.
30. Gach J, Quendler H, Strobach S, Katinger H, Kunert R, (2008) Structural analysis and in vivo administration of an anti-idiotypic antibody against mAb 2F5. Mol Immunol 45: 1027-1034.
31. Mader A, Kunert R, (2010) Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41. Protein Eng Des Sel 23: 947-954.
32. Waldmann TA, (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601.
33. Rodrigues L, Bonorino C, (2009) Role of IL-15 and IL-21 in viral immunity: applications for vaccines and therapies. Expert Rev Vaccines 8: 167-177.
34. Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, et al. (2007) Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol 81: 8774-8783.
35. Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, et al. (2010) Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 17: 793-801.
36. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, et al. (1989) Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 19: 2237-2242.
37. Kaumaya PT, Kobs-Conrad S, Seo YH, Lee H, VanBuskirk AM, et al. (1993) Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J Mol Recognit 6: 81-94.
38. Benferhat R, Martinon F, Krust B, Le Grand R, Hovanessian AG, (2009) The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. Mol Immunol 46: 705-712.
39. Kunert R, Wolbank S, Stiegler G, Weik R, Katinger H, (2004) Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses 20: 755-762.
40. Knappskog S, Ravneberg H, Gjerdrum C, Trösse C, Stern B, et al. (2007) The level of synthesis and secretion of Gaussia princeps luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide. J Biotechnol 128: 705-715.
41. Ho PC, Mutch DA, Winkel KD, Saul AJ, Jones GL, et al. (1990) Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol 20: 477-483.
42. Urlaub G, Chasin L, (1980) Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci U S A 77: 4216-4220.
43. Jeffs SA, Goriup S, Kebble B, Crane D, Bolgiano B, et al. (2004) Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 22: 1032-1046.
44. Abdiche YN, Malashock DS, Pinkerton A, Pons J, (2009) Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. Anal Biochem 386: 172-180.
45. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
46. Zhang MY, Wang Y, Mankowski MK, Ptak RG, Dimitrov DS, (2009) Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 27: 857-863.
47. Kim M, Qiao Z, Yu J, Montefiori D, Reinherz EL, (2007) Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 25: 5102-5114.
48. Wang Z, Liu Z, Cheng X, Chen YH, (2005) The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41. Microbiol Immunol 49: 703-709.
49. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, et al. (2002) Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 277: 45811-45820.
50. Ho J, MacDonald KS, Barber BH, (2002) Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine 20: 1169-1180.
51. Lorizate M, Cruz A, Huarte N, Kunert R, Pérez-Gil J, et al. (2006) Recognition and blocking of HIV-1 gp41 pre-transmembrane sequence by monoclonal 4E10 antibody in a Raft-like membrane environment. J Biol Chem 281: 39598-39606.
52. Menendez A, Chow KC, Pan OC, Scott JK, (2004) Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J Mol Biol 338: 311-327.
53. Ofek G, Tang M, Sambor A, Katinger H, Mascola J, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78: 10724-10737.
54. Cardoso R, Zwick M, Stanfield R, Kunert R, Binley J, et al. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163-173.
55. Julien JP, Bryson S, Nieva JL, Pai EF, (2008) Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol 384: 377-392.
56. Bryson S, Julien JP, Hynes RC, Pai EF, (2009) Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol 83: 11862-11875.
57. Alam SM, Morelli M, Dennison SM, Liao HX, Zhang R, et al. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 106: 20234-20239.
58. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR, (2010) Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 107: 1529-1534.
59. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, et al. (2010) Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 84: 2955-2962.
60. Bryson S, Julien J, Isenman D, Kunert R, Katinger H, et al. (2008) Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6. J Mol Biol 382: 910-919.
61. Gach JS, Maurer M, Hahn R, Gasser B, Mattanovich D, et al. (2007) High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris. J Biotechnol 128: 735-746.